Physician profile
Victoria Olvera
NPI 1225782154
$566.23
in general payments reported to CMS, 2019-2025
14 companies · $113 in 2025
The $113 reported for 2025 was more than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.59 · 2023: $158 · 2024: $276 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $155.81 | 2023-2025 | Doc Band |
| Sanofi Pasteur INC. | $114.60 | 2023-2024 | |
| Ironshore Pharmaceuticals INC. | $52.66 | 2024 | |
| Seqirus USA INC | $45.70 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Lnhc, INC | $27.94 | 2025 | Zelsuvmi |
| Vertical Pharmaceuticals, LLC | $23.26 | 2024 | Relexxii |
| Glaxosmithkline, LLC. | $19.59 | 2022 | |
| Pfizer INC. | $19.35 | 2024 | |
| Kaleo, INC. | $18.76 | 2023 | Auvi-Q |
| Collegium Pharmaceutical, INC. | $18.45 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $18.27 | 2024 | Ycanth |
| Merck Sharp & Dohme LLC | $17.92 | 2024 | Gardasil, Gardasil 9, M-M-R II |
| Ultragenyx Pharmaceutical INC. | $17.61 | 2024 | Crysvita |
| Neos Therapeutics, LP | $16.31 | 2024 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Olvera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.